User: Guest  Login
Less Searchfields
Simple search
Title:

Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers.

Document type:
Journal Article
Author(s):
Koch, Christine; Göller, Markus; Schott, Eckart; Waidmann, Oliver; Op den Winkel, Mark; Paprottka, Philipp; Zangos, Stephan; Vogl, Thomas; Bechstein, Wolf Otto; Zeuzem, Stefan; Kolligs, Frank T; Trojan, Jörg
Abstract:
BACKGROUND AND AIMS: Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. METHODS: A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. RESULTS: A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3-9.7), 4.1 months (95% CI: 3.6-4.7) and 5.0 months (95% CI: 2.9-7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0-18.1), 8.4 months (95% CI: 6.0-10.8) and 10.5 months (95% CI: 7.5-13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. CONCLUSIONS: Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
Journal title abbreviation:
Cancers (Basel)
Year:
2021
Journal volume:
13
Journal issue:
9
Fulltext / DOI:
doi:10.3390/cancers13092121
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/33924810
TUM Institution:
Professur für Interventionelle Radiologie (Prof. Paprottka)
 BibTeX